Zum Hauptinhalt springen Zur Suche springen Zur Hauptnavigation springen
Beschreibung
NATIONAL BESTSELLER The gripping story of Elizabeth Holmes and Theranosone of the biggest corporate frauds in history a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.

Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection. The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes s worth at an estimated [...] billion. There was just one problem: The technology didn t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings from journalists to their own employees. / Ausgezeichnet: Financial Times and McKinsey Business Book of the Year Award, 2018.
NATIONAL BESTSELLER The gripping story of Elizabeth Holmes and Theranosone of the biggest corporate frauds in history a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.

Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection. The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes s worth at an estimated [...] billion. There was just one problem: The technology didn t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings from journalists to their own employees. / Ausgezeichnet: Financial Times and McKinsey Business Book of the Year Award, 2018.
Zusammenfassung
John Carreyrou, a two-time Pulitzer Prize winner, was a reporter at The Wall Street Journal for twenty years. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. Bad Blood was named the Financial Times and McKinsey Business Book of the Year. Carreyrou lives in Brooklyn, New York, with his wife and three children.
Details
Erscheinungsjahr: 2020
Fachbereich: Wirtschaft International
Genre: Wirtschaft
Rubrik: Recht & Wirtschaft
Medium: Taschenbuch
Inhalt: VI
438 S.
8 s/w Bildtaf.
ISBN-13: 9780593081648
ISBN-10: 0593081641
Sprache: Englisch
Einband: Paperback
Autor: Carreyrou, John
Auflage: INT
Hersteller: Vintage
Penguin Random House
Verantwortliche Person für die EU: Petersen Buchimport GmbH, Vertrieb, Weidestr. 122a, D-22083 Hamburg, gpsr@petersen-buchimport.com
Maße: 173 x 106 x 29 mm
Von/Mit: John Carreyrou
Erscheinungsdatum: 28.01.2020
Gewicht: 0,229 kg
Artikel-ID: 117420355

Ähnliche Produkte